Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Gross Profit (2022 - 2025)

Oramed Pharmaceuticals' Gross Profit history spans 3 years, with the latest figure at $13000.0 for Q1 2025.

  • For Q1 2025, Gross Profit changed N/A year-over-year to $13000.0; the TTM value through Dec 2025 reached $13000.0, changed N/A, while the annual FY2025 figure was $13000.0, N/A changed from the prior year.
  • Gross Profit reached $13000.0 in Q1 2025 per ORMP's latest filing, up from -$663000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $482000.0 in Q1 2023 to a low of -$663000.0 in Q3 2023.
  • Average Gross Profit over 3 years is $129000.0, with a median of $219000.0 recorded in 2022.
  • The largest YoY upside for Gross Profit was 534.21% in 2023 against a maximum downside of 402.74% in 2023.
  • A 3-year view of Gross Profit shows it stood at $219000.0 in 2022, then plummeted by 402.74% to -$663000.0 in 2023, then skyrocketed by 101.96% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gross Profit are $13000.0 (Q1 2025), -$663000.0 (Q3 2023), and $482000.0 (Q2 2023).